These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8954169)

  • 1. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
    Schwendener RA; Schott H
    J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
    Schwendener RA; Horber DH; Odermatt B; Schott H
    J Cancer Res Clin Oncol; 1996; 122(2):102-8. PubMed ID: 8576276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
    Schott H; Schwendener RA
    Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
    Horber DH; Cattaneo-Pangrazzi RM; von Ballmoos P; Schott H; Ludwig PS; Eriksson S; Fichtner I; Schwendener RA
    J Cancer Res Clin Oncol; 2000 Jun; 126(6):311-9. PubMed ID: 10870640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
    Schwendener RA; Schott H
    Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R; Schott H
    Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of leukemia L1210 and P388 by arabinosylcytosine-polysaccharide conjugates.
    Novotný L; Balázová E; Sandula J; Ujházy V; Kéry V
    Int J Cancer; 1991 Jan; 47(2):281-4. PubMed ID: 1988371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemic activity of sulfonamide conjugates of arabinosylcytosine.
    Novotny L; Phillips OA; Rauko P; Miadokova E
    Exp Oncol; 2006 Dec; 28(4):293-8. PubMed ID: 17285113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
    Rentsch KM; Schwendener RA; Schott H; Hänseler E
    J Pharm Pharmacol; 1997 Nov; 49(11):1076-81. PubMed ID: 9401941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
    Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
    Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
    Balzarini J; De Clercq E
    Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine.
    Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi J; Ishida T
    Cancer Res; 1976 Aug; 36(8):2726-32. PubMed ID: 1277182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 2,2'-anhydro-1-(3'-Ok-acetyl-beta-D-arabinofuranosyl)-5-iodocytosine hydrochloride and related compounds as antineoplastic and antiviral agents.
    Itoh YH; Chu MY; Chang PK; Allaudeen HS; Sartorelli AC
    Chem Biol Interact; 1981 Jan; 33(2-3):215-27. PubMed ID: 6257405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
    Chwang TL; Fridland A; Avery TL
    J Med Chem; 1983 Feb; 26(2):280-3. PubMed ID: 6827546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
    Schwendener RA; Friedl K; Depenbrock H; Schott H; Hanauske AR
    Invest New Drugs; 2001; 19(3):203-10. PubMed ID: 11561676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
    Koller-Lucae SK; Schott H; Schwendener RA
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1572-80. PubMed ID: 9316874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
    Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
    Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.